In opposition to its antitumor role in HCC model, M2-derived miR-223 has been previously shown to stimulate proliferation in breast cancer cells because of the targeting of Mef2c/β-catenin pathway related to the inhibition of cell migration [163, 173, 174]. Here, MEF2C is linked to breast carcinoma.